{
    "clinical_study": {
        "@rank": "87328", 
        "arm_group": {
            "arm_group_label": "pre and 12 months post ENT", 
            "arm_group_type": "Experimental", 
            "description": "Compare the clinical status of CFS patients after at least 12 months of ENT to their status before ENT.\nENT consists of:\nDaily conditioning exercise: 35-40 minutes\nNutraceutical supplements: acetyl-L-carnitine 500 mg bid, alpha-lipoic acid (Alpha Lipoic Sustain 300) 300 mg qd, CoQ10 (Ubiquinol QH-absorb) 100 mg qd, docosahexanoic acid (maxDHA) 300 mg qd, plus a multivitamin (Centrum Silver) \u00bd tab bid.\nDiet: 25% protein, 35- 40% carbohydrate, 35-40% fat"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study was to determine whether therapy that has been shown to be\n      beneficial for mitochondrial diseases is also beneficial for Chronic Fatigue Syndrome (CFS)\n      patients. Patients received daily conditioning exercise, a high protein diet and\n      nutraceutical therapy (ENT). Prescribed nutraceutical supplements are alpha-lipoic acid,\n      acetyl-L-carnitine, omega-3fatty acids (maxDHA), coenzyme Q10 (CoQ10), plus a multivitamin."
        }, 
        "brief_title": "Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder", 
        "completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Fatigue Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Fatigue", 
                "Fatigue Syndrome, Chronic", 
                "Mitochondrial Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The etiology and pathogenesis of chronic fatigue syndrome (CFS) is poorly understood.\n      Although therapies have been proposed, none has been particularly effective. A preceding\n      viral infection is believed to cause mitochondrial dysfunction in genetically susceptible\n      individuals, resulting in overwhelming fatigue, myalgia and brain fuzziness. The purpose of\n      this study was to determine whether therapy that has been shown to be beneficial for\n      mitochondrial diseases is also beneficial for CFS.\n\n      Patients received daily conditioning exercise, a high protein diet and nutraceutical therapy\n      (ENT). Prescribed nutraceutical supplements are alpha-lipoic acid, acetyl-L-carnitine,\n      omega-3fatty acids (maxDHA), coenzyme Q10 (CoQ10), plus a multivitamin, which were selected\n      to enhance mitochondrial function and antioxidant action. Following the institution of ENT,\n      patients have received this therapy for varying lengths of time, ranging from 12 to 40\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Severe chronic fatigue for 6 or more consecutive months 4 or more of the following 8\n        symptoms concurrently:\n\n          -  post-exertion malaise lasting more than 24 hours\n\n          -  unrefreshing sleep\n\n          -  significant impairment of short-term memory or concentration\n\n          -  muscle pain\n\n          -  pain in the joints without swelling or redness\n\n          -  headaches of a new type, pattern, or severity\n\n          -  tender lymph nodes in the neck or armpit\n\n          -  a sore throat that is frequent or recurring These symptoms should have persisted or\n             recurred during 6 or more consecutive months of illness and they cannot have first\n             appeared before the fatigue.\n\n        Exclusion Criteria:\n\n          -  Additional medical illnesses causing chronic fatigue\n\n          -  Ongoing exertion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "66 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872351", 
            "org_study_id": "AAAI1410"
        }, 
        "intervention": {
            "arm_group_label": "pre and 12 months post ENT", 
            "intervention_name": "Nutraceuticals", 
            "intervention_type": "Drug", 
            "other_name": [
                "Jarrow Formulas:", 
                "- acetyl-L-carnitine 500 mg bid", 
                "- alpha-lipoic acid (Alpha Lipoic Sustain 300) 300 mg qd", 
                "- CoQ10 (Ubiquinol QH-absorb) 100 mg qd", 
                "- docosahexanoic acid (maxDHA) 300 mg qd", 
                "Pfizer Consumer Healthcare:", 
                "- multivitamin (Centrum Silver) \u00bd tab bid"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcarnitine", 
                "Thioctic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "chronic fatigue syndrome", 
            "mitochondrial disorder", 
            "conditioning exercise", 
            "nutraceutical supplements", 
            "high protein diet"
        ], 
        "lastchanged_date": "June 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10032"
                }, 
                "name": "Columbia University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Benefit of Conditioning Exercise, High Protein Diet and Nutraceutical Supplements in Chronic Fatigue Syndrome: a Presumptive Mitochondrial Disorder", 
        "other_outcome": {
            "measure": "Compliance Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "First 6 months vs. last 6 months of therapy"
        }, 
        "overall_official": {
            "affiliation": "Columbia University", 
            "last_name": "Alfred Slonim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Modified Fatigue Severity Score", 
            "safety_issue": "No", 
            "time_frame": "6-40 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872351"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Columbia University", 
            "investigator_full_name": "Alfred E. Slonim", 
            "investigator_title": "Professor of Clinical Pediatrics", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Assess pre/post symptoms of CFS not covered by the Modified Fatigue Severity Score", 
            "measure": "Other Symptoms Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "6-40 months"
        }, 
        "source": "Columbia University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alfred E. Slonim", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}